715 related articles for article (PubMed ID: 15273746)
1. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Sznajer Y; Keren B; Baumann C; Pereira S; Alberti C; Elion J; Cavé H; Verloes A
Pediatrics; 2007 Jun; 119(6):e1325-31. PubMed ID: 17515436
[TBL] [Abstract][Full Text] [Related]
3. Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Roberts AE; Araki T; Swanson KD; Montgomery KT; Schiripo TA; Joshi VA; Li L; Yassin Y; Tamburino AM; Neel BG; Kucherlapati RS
Nat Genet; 2007 Jan; 39(1):70-4. PubMed ID: 17143285
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
5. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
[TBL] [Abstract][Full Text] [Related]
6. PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.
Schollen E; Matthijs G; Gewillig M; Fryns JP; Legius E
Eur J Hum Genet; 2003 Jan; 11(1):85-8. PubMed ID: 12529711
[TBL] [Abstract][Full Text] [Related]
7. Germline KRAS mutations cause Noonan syndrome.
Schubbert S; Zenker M; Rowe SL; Böll S; Klein C; Bollag G; van der Burgt I; Musante L; Kalscheuer V; Wehner LE; Nguyen H; West B; Zhang KY; Sistermans E; Rauch A; Niemeyer CM; Shannon K; Kratz CP
Nat Genet; 2006 Mar; 38(3):331-6. PubMed ID: 16474405
[TBL] [Abstract][Full Text] [Related]
8. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
10. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
Tartaglia M; Mehler EL; Goldberg R; Zampino G; Brunner HG; Kremer H; van der Burgt I; Crosby AH; Ion A; Jeffery S; Kalidas K; Patton MA; Kucherlapati RS; Gelb BD
Nat Genet; 2001 Dec; 29(4):465-8. PubMed ID: 11704759
[TBL] [Abstract][Full Text] [Related]
11. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
12. Mild variable Noonan syndrome in a family with a novel PTPN11 mutation.
Zenker M; Voss E; Reis A
Eur J Med Genet; 2007; 50(1):43-7. PubMed ID: 17052965
[TBL] [Abstract][Full Text] [Related]
13. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
Mohi MG; Williams IR; Dearolf CR; Chan G; Kutok JL; Cohen S; Morgan K; Boulton C; Shigematsu H; Keilhack H; Akashi K; Gilliland DG; Neel BG
Cancer Cell; 2005 Feb; 7(2):179-91. PubMed ID: 15710330
[TBL] [Abstract][Full Text] [Related]
14. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
[TBL] [Abstract][Full Text] [Related]
15. Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene.
Abadir S; Edouard T; Julia S
Cardiol Young; 2007 Feb; 17(1):95-7. PubMed ID: 17184563
[TBL] [Abstract][Full Text] [Related]
16. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Krenz M; Yutzey KE; Robbins J
Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
[TBL] [Abstract][Full Text] [Related]
17. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.
Musante L; Kehl HG; Majewski F; Meinecke P; Schweiger S; Gillessen-Kaesbach G; Wieczorek D; Hinkel GK; Tinschert S; Hoeltzenbein M; Ropers HH; Kalscheuer VM
Eur J Hum Genet; 2003 Feb; 11(2):201-6. PubMed ID: 12634870
[TBL] [Abstract][Full Text] [Related]
19. PTPN11 mutations are not responsible for the Cardiofaciocutaneous (CFC) syndrome.
Kavamura MI; Pomponi MG; Zollino M; Lecce R; Murdolo M; Brunoni D; Alchorne MM; Opitz JM; Neri G
Eur J Hum Genet; 2003 Jan; 11(1):64-8. PubMed ID: 12529707
[TBL] [Abstract][Full Text] [Related]
20. Genetics and variation in phenotype in Noonan syndrome.
Jongmans M; Otten B; Noordam K; van der Burgt I
Horm Res; 2004; 62 Suppl 3():56-9. PubMed ID: 15539800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
